SCHEMBL1562889

SCHEMBL1562889

O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCN(CCO)CC2)c1O)Nc1cccc(F)c1Cl

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 20/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1562893 0.89 CXCR2 (0.79) CXCR2
SCHEMBL1562925 0.88 CXCR2 (1.00) CXCR2
Hydrochloric Acid SCHEMBL4355911 0.87 CXCR2 (0.98) CXCR2
SCHEMBL13096283 0.85 CXCR2 (0.79) CXCR2
Elubrixin SCHEMBL30515706 0.84 CXCR2 (1.00) CXCR2
Elubrixin SCHEMBL1562280 0.84 CXCR2 (1.00) CXCR2
Elubrixin SCHEMBL1741720 0.83 CXCR2 (0.98) CXCR2
SCHEMBL4616300 0.83 CXCR2 (0.78) CXCR2
SCHEMBL4162988 0.81 CXCR2 (0.84) CXCR2
SCHEMBL1562600 0.80 CXCR2 (0.74) CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2388006-A1 Urea derivatives as IL-8 receptor antagonists GlaxoSmithKline LLC (US) 2011-11-23 EP claimed
US-20110253866-A1 SWINGING SUPPORT DEVICE PANASONIC CORPORATION (JP) 2011-10-20 US claimed
EP-1558259-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2009-04-08 EP claimed
US-20060040952-A1 Il-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2006-02-23 US claimed
EP-1558259-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-03 EP claimed
WO-2004039775-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-05-13 WO claimed
EP-2388006-A1 Urea derivatives as IL-8 receptor antagonists GlaxoSmithKline LLC (US) 2011-11-23 EP disclosed
US-20110253866-A1 SWINGING SUPPORT DEVICE PANASONIC CORPORATION (JP) 2011-10-20 US disclosed
EP-1558259-B1 Urea derivatives as IL-8 receptor antagonists GLAXOSMITHKLINE LLC (US) 2011-04-06 EP disclosed
US-7709485-B2 IL-8 receptor antagonists GLAXOSMITHKLINE LLC (US) 2010-05-04 US disclosed
US-20090093492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION 2009-04-09 US disclosed
EP-1558259-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2009-04-08 EP disclosed
US-20070249625-A1 Il-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2007-10-25 US disclosed
US-20060040952-A1 Il-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2006-02-23 US disclosed
EP-1558259-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-03 EP disclosed
WO-2004039775-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040952-A1 Il-8 receptor antagonists CXCL8, CCR8, IL1RN CXCR2 9/4885
US-20070249625-A1 Il-8 Receptor Antagonists CXCL8, CCR8, IL1RN CXCR2 9/4885
US-20090093492-A1 IL-8 RECEPTOR ANTAGONISTS CXCL8, CCR8, IL1RN CXCR2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.